Defense Attorneys Portray Melgen, Menendez as Friends in Opening Arguments of Corruption Trial

September 8, 2017: By Joan McKenna
Salomon Melgen

Salomon Melgen

Defense attorneys for Florida retina specialist Salomon Melgen and US Sen. Bob Menendez, D-NJ, are building a portrait of their clients as simply friends in a federal corruption trial that got underway Sept. 6 in New Jersey. Prosecutors allege the defendants’ behavior amounted to bribery.

The jury trial is examining whether Menendez lobbied for Melgen’s business interests in exchange for gifts and political donations. It is expected to last nearly two months.

Both defendants have pleaded not guilty.

Justice Department allegations include a claim that Menendez intervened to help Melgen try to resolve his $8.9 million billing dispute with Medicare in 2009, after the Centers for Medicare and Medicaid Services accused Melgen of overbilling for Lucentis vials.

Menendez in return received luxury trips, flights on private jets, and hundreds of thousands of dollars in campaign donations, prosecutors claim.

US District Judge William Walls has shown little patience for courtroom antics and “irrelevant” details about swanky hotels, saying Sept. 7 that he was “not going to let this be a tabloid trial.”

In a separate trial earlier in 2017, Melgen, 62, was convicted of 67 counts of Medicare fraud. A sentencing hearing was postponed Aug. 10, a day before it was to set to start, as all parties agreed to move it to December due the current trial.

Melgen, who operated the now closed Vitreo-Retinal Consultants of the Palm Beaches, surrendered his medical license following the conviction, CNN reported Sept. 5.

Melgen is not expected to testify against Menendez, cooling speculation that prosecutors were trying to get Melgen to turn on Menendez for a lesser sentence.

In Melgen’s trial, he was accused of falsely diagnosing patients with macular degeneration and other retinal disorders, performing unnecessary procedures, and overcharging for Lucentis by splitting single-use bottles into multiple doses but charging Medicare per patient.

US prosecutors alleged that, between January 2008 and December 2013, Melgen billed Medicare for more than $190 million, for which he was reimbursed more than $105 million. The government said a substantial portion of these payments were obtained through fraudulent billing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023